Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Dry Skin, Sensitive Skin, Dry Skin in the Elderly, Dietary Supplement

In brief

This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.

Key facts

Study ID

NCT07529249

Run by

Centre de Pharmacologie Clinique Applique a la Dermatologie

People needed

75

Starts

2026-04-01

Expected to finish

2026-09-01

Last updated by the study team

2026-05-12

Who can join

Age: 45 and older, up to 70. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Participant having signed an Informed Consent Form (ICF);
• Healthy female Participant aged 45 to 70 years inclusive not followed by a healthcare practitioner for any skin disease;
• Participant with phototype II to IV according to the Fitzpatrick classification;
• Participant with dry skin measured on the cheeks (Tewameter, TEWL >15g/m²/h (skin barrier integrity) on back of the cheekbone)
• Female Participant of non-childbearing potential, defined as a woman without uterus and/or both ovaries, surgically sterile (at least 6 months prior to Screening visit) or post-menopausal (at least one year post cessation of menses);
• Female Participant of childbearing potential who has been using a highly effective birth control method for at least 1 month prior to Screening visit and agreeing to continue adequate contraception during the entire study period;
• Highly effective birth control methods are:
• hormonal (combined or progestogen-only) contraception methods associated with inhibition of ovulation or intrauterine device; bilateral tubal occlusion since at least 3 months prior to Screening visit; vasectomised partner; True abstinence, i.e., refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant.
• Participant agreeing not to apply any cosmetic product (e.g. care cream, lotion, body milk) or drug on the face (except usual cleansing products) within 24 hours before the study visits;
• Participant agreeing to not apply cosmetic, medical, or aesthetic treatments out of the study protocol on the face and legs during the whole study duration;
• Participant affiliated to a health social security system (according to French Law).

You may not qualify if…

• Participant with a BMI ≤17 or ≥30 kg/cm²;
• Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;
• Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastrointestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;
• Participant with an history of sleeve or bypass;
• Participant currently participating in another clinical study or being in an exclusion period of another clinical study;
• Participant with known or suspected hypersensitivity to any component(s) of the investigational products or to any ingredients of the vehicles (i.e., excipients);
• Participant with a known allergy to beef-derived products;
• Participant who has used collagen supplements, vitamin C, or other skin related nutraceuticals within the last 3 months
• Participant who started using prescription medications to treat skin conditions or other medications that affect the skin during the three months prior to the study
• Participant who has made significant lifestyle changes in the past three months (altering their diet, starting new exercises, or changing their skincare routines)
• Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face and legs which could interfere with the study;
• Participant impossible to contact in case of emergency;
• Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);
• Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;
• Protected participant as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or participant to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person participant to a legal protection measure or unable to express his/her consent. Article L3212-1: person undergoing compulsory psychiatric treatment. Article L3213-1: person having a mental disorder that requires care and that which may compromise the safety of third persons or seriously undermine public order;
• Participant unable to communicate or cooperate with the Investigator;
• Participant having received 6000 euros indemnities for participation in clinical trials/investigations in the 12 previous months, including participation in the present study (according to French Law);

Where it is running

• CPCAD - Centre Pharmacologie Clinique Appliqué à la Dermatologie, CHU Nice — Nice, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.